论文部分内容阅读
目的分析和研究体腔热灌注化疗治疗恶性胸(腹)水的临床疗效。方法我们将2014年3月至2016年3月恶性胸(腹)水患者41例做为研究对象,41例患者均采用体腔热灌注化疗方法治疗,将其具体治疗方法与效果进行回顾性分析。结果 41例患者治疗有效率达至90.2%。患者治疗前与治疗8周后功能状态评分相比有较显著性差异P<0.05。41例患者治疗期间不良反应发生率为7.3%。结论将体腔热灌注化疗方法应用于恶性胸(腹)水患者治疗中,其能够有效促进胸、腹水吸收,利于改善患者机体功能状态,对延长患者生存时间及提高患者生存质量均具有重要作用。
Objective To analyze and study the clinical efficacy of intra-abdominal hyperthermic chemotherapy in the treatment of malignant thorax (abdomen) water. METHODS: Forty-one patients with malignant thoracic (abdominal) water from March 2014 to March 2016 were enrolled in this study. Forty-one patients were treated with intra-corporeal hyperthermic perfusion chemotherapy, and their specific treatment methods and effects were retrospectively analyzed. Results The effective rate of treatment in 41 patients reached 90.2%. Patients before treatment and 8 weeks after treatment functional status scores compared to a significant difference P <0.05.41 cases of patients treated during the adverse reaction rate was 7.3%. Conclusion The method of intraluminal hyperthermic perfusion chemotherapy in the treatment of patients with malignant thorax (abdomen) water can effectively promote the absorption of thoracic and ascitic fluid, and improve the functional status of patients. It plays an important role in prolonging the survival time and improving the quality of life of patients.